Radioactive 'Smart Bombs' target Hard-to-Treat cancers

NCT ID NCT07661641

Recruiting now Disease control Sponsor: Alpha-9 Oncology USA Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests two radioactive drugs, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, in people with advanced solid tumors that have a protein called GRPR on their surface. These cancers include certain breast, prostate, and colorectal cancers that have stopped responding to standard therapies. The study aims to find safe doses and check how the drugs spread in the body, using a third diagnostic agent to identify GRPR-positive tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutetium-177 and Actinium-225 attached to a molecule that targets GRPR
What this could lead to: If successful, this could provide a new targeted radiation therapy option for people with advanced GRPR-positive cancers that have stopped responding to standard treatments.
What could go wrong: This is a very early (Phase 1) trial, so the main goal is safety and dosing, not yet proving effectiveness. The radioactive drugs may cause side effects in healthy organs, and the trial is small, so results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm colorectal cancer colorectal neoplasm hormone receptor-positive breast cancer prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER COLORECTAL CANCER GRPR-POSITIVE SOLID TUMORS PROSTATE CANCER

Contacts and locations

Locations

GenesisCare Murdoch
NOT_YET_RECRUITING

Murdoch, Western Australia, 6150, Australia
Melbourne Theranostic Innovation Center
RECRUITING

Melbourne N., Victoria, 3051, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.